GlassScriptPhysician profile
David Tapscott
NPI 1255711370
$33,549.55
in general payments reported to CMS, 2019-2025
13 companies · $6,882 in 2025
The $6,882 reported for 2025 was more than what 85% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,115 · 2020: $10K · 2021: $14K · 2023: $356 · 2024: $29.92 · 2025: $6,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,400 · Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,400.00 |
| Food and Beverage | $867.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $15,300.00 | 2020-2021 | |
| Skeletal Dynamics INC | $6,446.05 | 2023-2025 | Align, Geminus, Implate |
| Encore Medical, LP | $4,980.11 | 2020-2021 | |
| Medical Device Business Services, INC. | $3,314.59 | 2020-2021 | |
| Zimmer Biomet Holdings, INC. | $1,659.46 | 2019-2025 | Affixus, Comprehensive Shoulder System, Ncb |
| Wardlow Enterprises | $1,035.00 | 2019 | |
| Biedermann Motech, INC. | $474.92 | 2021 | |
| Stryker Corporation | $100.81 | 2019 | |
| Depuy Synthes Sales INC. | $97.26 | 2020-2021 | |
| Catalyst Orthoscience | $74.98 | 2025 | Archer Csr Total Shoulder System, R1 Reverse Total Shoulder, Catalyst Total Csr |
| Biocomposites INC | $29.92 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $21.27 | 2025 | |
| Ferring Pharmaceuticals INC. | $15.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tapscott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.